Chylous Ascites, a Rare Adverse Reaction to Selpercatinib
Adriana Dias1, Joao O Pereira1, Daniela Madama1
1Pulmonology Department, Unidade Local de Saúde de Coimbra, Coimbra, PRT.
None:
Selpercatinib improves outcomes in Rearranged during Transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) but can rarely cause chylous ascites (CA). We report the case of a 53-year-old man with recurrent RET-positive lung adenocarcinoma who developed CA 17 months after starting selpercatinib. Reducing the selpercatinib dose and implementing a low long-chain triglyceride diet led to symptom relief, stable ascites, and maintained tumor response. This case highlights effective management of tyrosine kinase inhibitor (TKI)-induced CA without compromising cancer control.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Nephrotic Syndrome I : Introduction
